Table 1 Baseline characteristics of included studies.
Author (year)[Ref.] | Study design, Country | Participants/lost to follow-up, n | Diagnoses | Group | Duration of treatment | Outcomes |
|---|---|---|---|---|---|---|
Stöhrer (1991)12 | RCT, Germany | 61/6 | detrusor hyperreflexia from SCI | Placebo | 3-week | MCC, MDP, BC, Qmax, PVR |
Trospium chloride (20 mg Bid) | ||||||
Stöhrer (1999)13 | RCT, Germany | 113/11 | detrusor hyperreflexia from SCI | Placebo | 2-week | MCC, BC, PVR bladder capacity during onset of the first detrusor contraction, duration amplitude of the maximal detrusor contraction |
Propiverine (15 mg Tid) | ||||||
Stöhrer (2007)14 | RCT, Germany | 131/40 | detrusor overactivity from SCI | Propiverine (15 mg Tid) | 2-week | MCC, MDP, BC |
Oxybutynin (5 mg Tid) | ||||||
Madersbacher (1994)15 | RCT, Austria | 95/10 | detrusor hyperreflexia from SCI | Trospium chloride (20 mg Bid) | 2-week | MCC, MDP, BC, PVR |
Oxybutynin (5 mg Tid) | ||||||
Van Kerrebroeck (1998)16 | RCT, Netherlands | 90/14 | detrusor hyperreflexia from SCI | Placebo | 2-week | MCC, BC, PVR, Qmax, VpmaxIDC volume at normal desire to void |
Tolterodine (0.5 mg Bid) | ||||||
Tolterodine (1 mg Bid) | ||||||
Tolterodine (2 mg Bid) | ||||||
Tolterodine (4 mg Bid) | ||||||
Di Stasi (2001)17 | RCT, Italy | 12/0 | detrusor hyperreflexia from SCI | Placebo | single dose | IDC, BC, PVR, UI episodes per week |
Oxybutynin (5 mg Tid) | ||||||
Cruz (2011)18 | RCT, Canada | 275/45 | NDO from SCI or MS | Placebo | 6-week | MCC, PdetmaxIDC, VpmaxIDC, BC, UI episodes per week, incontinence quality of life, volume per void |
OnabotulinumtoxinA (200U) | ||||||
OnabotulinumtoxinA (300U) | ||||||
Apostolidis (2012)19 | RCT, Greece | 74/45 | NDO | Placebo | 12-week | MCC, PdetmaxIDC, VpmaxIDC, UI episodes per week, volume per void |
OnabotulinumtoxinA (50U) | ||||||
OnabotulinumtoxinA (100U) | ||||||
OnabotulinumtoxinA (200U) | ||||||
Ginsberg (2012)20 | RCT, America | 416/87 | NDO from SCI or MS | Placebo | 52-week | MCC, PdetmaxIDC, 7-day bladder diary, UI episodes per week, incontinence quality of life |
OnabotulinumtoxinA (200U) | ||||||
OnabotulinumtoxinA (300U) | ||||||
Rovner (2013)21 | RCT, America | 691/0 | NDO from SCI or MS | Placebo | 52-week | MCC, PdetmaxIDC, VpmaxIDC, BC, percentage of patients with no IDC on post-treatment urodynamics at 6 weeks, 7-day bladder diary |
OnabotulinumtoxinA (200U) | ||||||
OnabotulinumtoxinA (300U) | ||||||
Amarenco (2015)22 | RCT, France | 194/13 | NDO from SCI or MS | Placebo | 4-week | MCC, VpmaxIDC, MDP, micturition diary variables incontinence Quality of Life, Treatment Satisfaction Visual Analogue Scale, Euroqol 5-dimension questionnaire |
Oxybutynin (5 mg Tid) | ||||||
Solifenacin (5 mg Qd) | ||||||
Solifenacin (10 mg Qd) | ||||||
Ferreira (2018)23 | RCT, Brazil | 68/7 | NDO from SCI | Oxybutynin (5 mg Tid) | 24-week | MCC, PdetmaxIDC, BC, incontinence episodes in 24 h, 3-day bladder diary |
OnabotulinumtoxinA (300U) |
